Boothbay Fund Management
ESPR icon

Boothbay Fund Management’s Esperion Therapeutics ESPR Stock Holding History

Boothbay Fund Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-205
Closed -$823K – 779
2019
Q1 		$823K Sell
205
-71
-26% -$3.19K 0.08% 270
2018
Q4 		$1.27M Sell
276
-424
-61% -$20.4K 0.19% 110
2018
Q3 		$3.11M Buy
700
+277
+65% +$12.7K 0.31% 69
2018
Q2 		$1.66M Buy
423
+234
+124% +$11.8K 0.14% 116
2018
Q1 		$1.37M Buy
+189
New +$13.9K 0.16% 130

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Boothbay Fund Management's ESPR Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 30,000 shares worth $94.8K. The stake represents ﹤0.01% of the portfolio and ranks #2058 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ESPR as recently as Q3 2024.

Boothbay Fund Management first reported a position in ESPR in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.76M in Q3 2022. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Boothbay Fund Management held 30,000 shares of Esperion Therapeutics worth $94.8K as of Q2 2026.
  • Esperion Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2058 holding.
  • Boothbay Fund Management first reported a position in Esperion Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Boothbay Fund Management's Esperion Therapeutics position peaked at $1.76M in Q3 2022.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.